Shopping Cart
Remove All
Your shopping cart is currently empty
Abituzumab (Synonyms: EMD525797, EMD 525797, DI17E6, DI 17E6)
Catalog No. T76736 Copy Product Info
🥰Excellent
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
Abituzumab
Copy Product Info🥰Excellent
Catalog No. T76736
Synonyms EMD525797, EMD 525797, DI17E6, DI 17E6
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
Abituzumab
Cas No. 1105038-73-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $476 | In Stock | In Stock | |
| 10 mg | $787 | - | In Stock | |
| 25 mg | $1,170 | - | In Stock | |
| 50 mg | $1,580 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.44% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research. |
| In vitro | Methods: Prostate cancer cell lines were inoculated into 24-well plates and treated with Abituzumab (0.01, 0.1,1,10, 30,100μg/ml). The wound space was measured every 6 hours to observe the invasion and movement of cells. Results: Abituzumab inhibited the movement and invasion of PCa cells. Methods: Prostate cancer cell lines were treated with Abituzumab (100μg/ml) and incubated for 24h. Results: Abituzumab inhibited αV integrin expression and phosphorylation of FAK, Akt and ERK in LNCaP and C4-2B cells. [1] |
| Synonyms | EMD525797, EMD 525797, DI17E6, DI 17E6 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Integrin aV/ITGAV/CD51 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 1105038-73-0 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Abituzumab | purchase Abituzumab | Abituzumab cost | order Abituzumab | Abituzumab in vitro | Abituzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.